Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy

Jialin LIU; Xianyu ZHANG; Da PANG

doi:10.19401/j.cnki.1007-3639.2023.04.010

您当前的位置：

首页 >

文章列表页 >

Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy

Review | 更新时间：2025-12-31

- Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy
- China Oncology Vol. 33, Issue 4, Pages: 397-402(2023)
- 作者机构：
  
  哈尔滨医科大学附属肿瘤医院乳腺外科，黑龙江哈尔滨 150000
- 作者简介：
  
  PANG Da.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.04.010
  CLC： R730.5
- Received：20 June 2022，
  
  Revised：2022-10-17，
  
  Published：30 April 2023
- 稿件说明：
移动端阅览
Jialin LIU, Xianyu ZHANG, Da PANG. Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy[J]. China Oncology, 2023, 33(4): 397-402.
DOI：

Jialin LIU, Xianyu ZHANG, Da PANG. Research progress of adaptive therapy strategy based on Darwinian dynamics in tumor therapy[J]. China Oncology, 2023, 33(4): 397-402. DOI： 10.19401/j.cnki.1007-3639.2023.04.010.

摘要

辅助化疗药物和靶向治疗药物的应用极大地改善了晚期癌症患者的预后，但很快出现的耐药问题以及随之而来的病情迅速进展一直是癌症治疗领域的痛点。揉合了达尔文演化动力学的肿瘤适应性治疗（adaptive therapy，AT）是有别于传统最大耐受剂量（maximum tolerated dose，MTD）的新颖治疗理念，有望颠覆晚期癌症的治疗范式，实现患者长期的低负荷带瘤生存。本文对适应性治疗理论研究进展以及数学模型在优化适应性治疗策略中的重要地位进行综述，并对基于达尔文演化动力学的其他肿瘤治疗策略予以简述，以期为临床医师提供新的思路。

Abstract

The applications of adjuvant chemotherapy and targeted drugs have greatly improved the prognosis of patients with advanced cancer

however the rapid emergence of drug resistance and the subsequent rapid progress of the disease have always been the unmet challenges in the field of cancer treatment. Adaptive therapy (AT) combined with Darwinian evolutionary dynamics is a new treatment concept different from the traditional maximum tolerated dose (MTD)

which is expected to overturn the treatment paradigm of advanced cancer and achieve long-term low load tumor bearing survival. This paper reviewed the theory of AT and the important role of mathematical models in optimizing adaptive treatment strategies

then briefly described other tumor treatment strategies based on Darwinian dynamics

in order to provide new ideas for clinicians in the game with advanced cancer.

关键词

Keywords

references

CHEN Y L , CHANG M C , CHENG W F . Metronomic chemotherapy and immunotherapy in cancer treatment [J ] . Cancer Lett , 2017 , 400 : 282 - 292 . DOI: 10.1016/j.canlet.2017.01.040 http://doi.org/10.1016/j.canlet.2017.01.040 https://linkinghub.elsevier.com/retrieve/pii/S0304383517300824 https://linkinghub.elsevier.com/retrieve/pii/S0304383517300824

GATENBY R A , BROWN J S . Integrating evolutionary dynamics into cancer therapy [J ] . Nat Rev Clin Oncol , 2020 , 17 ( 11 ): 675 - 686 . DOI: 10.1038/s41571-020-0411-1 http://doi.org/10.1038/s41571-020-0411-1

MCGRANAHAN N , SWANTON C . Biological and therapeutic impact of intratumor heterogeneity in cancer evolution [J ] . Cancer Cell , 2015 , 27 ( 1 ): 15 - 26 . DOI: 10.1016/j.ccell.2014.12.001 http://doi.org/10.1016/j.ccell.2014.12.001

JOHNSON D B , MENZIES A M , ZIMMER L , et al . Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms [J ] . Eur J Cancer , 2015 , 51 ( 18 ): 2792 - 2799 . DOI: 10.1016/j.ejca.2015.08.022 http://doi.org/10.1016/j.ejca.2015.08.022

ENRIQUEZ-NAVAS P M , WOJTKOWIAK J W , GATENBY R A . Application of evolutionary principles to cancer therapy [J ] . Cancer Res , 2015 , 75 ( 22 ): 4675 - 4680 .

SHAFFER S M , DUNAGIN M C , TORBORG S R , et al . Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance [J ] . Nature , 2017 , 546 ( 7658 ): 431 - 435 . DOI: 10.1038/nature22794 http://doi.org/10.1038/nature22794 http://www.nature.com/articles/nature22794 http://www.nature.com/articles/nature22794

SAUNDERS N A , SIMPSON F , THOMPSON E W , et al . Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives [J ] . EMBO Mol Med , 2012 , 4 ( 8 ): 675 - 684 . DOI: 10.1002/emmm.201101131 http://doi.org/10.1002/emmm.201101131

GATENBY R A , SILVA A S , GILLIES R J , et al . Adaptive therapy [J ] . Cancer Res , 2009 , 69 ( 11 ): 4894 - 4903 . DOI: 10.1158/0008-5472.CAN-08-3658 http://doi.org/10.1158/0008-5472.CAN-08-3658

SIRAVEGNA G , MUSSOLIN B , BUSCARINO M , et al . Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients [J ] . Nat Med , 2015 , 21 ( 7 ): 827 . DOI: 10.1038/nm0715-827b http://doi.org/10.1038/nm0715-827b

SCHREUER M , JANSEN Y , PLANKEN S , et al . Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial [J ] . Lancet Oncol , 2017 , 18 ( 4 ): 464 - 472 . DOI: 10.1016/S1470-2045(17)30171-7 http://doi.org/10.1016/S1470-2045(17)30171-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301717 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301717

SMALLEY I , KIM E , LI J N , et al . Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma [J ] . EBioMedicine , 2019 , 48 : 178 - 190 . DOI: S2352-3964(19)30627-9 http://doi.org/S2352-3964(19)30627-9

ZHANG J S , CUNNINGHAM J J , BROWN J S , et al . Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer [J ] . Nat Commun , 2017 , 8 ( 1 ): 1816 . DOI: 10.1038/s41467-017-01968-5 http://doi.org/10.1038/s41467-017-01968-5

ENRIQUEZ-NAVAS P M , KAM Y , DAS T , et al . Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer [J ] . Sci Transl Med , 2016 , 8 ( 327 ): 327ra24 .

SILVA A S , KAM Y , KHIN Z P , et al . Evolutionary approaches to prolong progression-free survival in breast cancer [J ] . Cancer Res , 2012 , 72 ( 24 ): 6362 - 6370 . DOI: 10.1158/0008-5472.CAN-12-2235 http://doi.org/10.1158/0008-5472.CAN-12-2235

BACEVIC K , NOBLE R , SOFFAR A , et al . Spatial competition constrains resistance to targeted cancer therapy [J ] . Nat Commun , 2017 , 8 ( 1 ): 1995 . DOI: 10.1038/s41467-017-01516-1 http://doi.org/10.1038/s41467-017-01516-1

STROBL M A R , WEST J , VIOSSAT Y , et al . Turnover modulates the need for a cost of resistance in adaptive therapy [J ] . Cancer Res , 2021 , 81 ( 4 ): 1135 - 1147 . DOI: 10.1158/0008-5472.CAN-20-0806 http://doi.org/10.1158/0008-5472.CAN-20-0806

VIOSSAT Y , NOBLE R . A theoretical analysis of tumour containment [J ] . Nat Ecol Evol , 2021 , 5 ( 6 ): 826 - 835 . DOI: 10.1038/s41559-021-01428-w http://doi.org/10.1038/s41559-021-01428-w

CUNNINGHAM J , THUIJSMAN F , PEETERS R , et al . Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer [J ] . PLoS One , 2020 , 15 ( 12 ): e0243386 . DOI: 10.1371/journal.pone.0243386 http://doi.org/10.1371/journal.pone.0243386 https://dx.plos.org/10.1371/journal.pone.0243386 https://dx.plos.org/10.1371/journal.pone.0243386

BELKHIR S , THOMAS F , ROCHE B . Darwinian approaches for cancer treatment: benefits of mathematical modeling [J ] . Cancers , 2021 , 13 ( 17 ): 4448 . DOI: 10.3390/cancers13174448 http://doi.org/10.3390/cancers13174448 https://www.mdpi.com/2072-6694/13/17/4448 https://www.mdpi.com/2072-6694/13/17/4448

KIMKO H , PINHEIRO J . Model-based clinical drug development in the past, present and future: a commentary [J ] . Br J Clin Pharmacol , 2015 , 79 ( 1 ): 108 - 116 . DOI: 10.1111/bcp.12341 http://doi.org/10.1111/bcp.12341

YIN A Y , VAN HASSELT J G C , GUCHELAAR H J , et al . Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance [J ] . Sci Rep , 2022 , 12 ( 1 ): 4206 . DOI: 10.1038/s41598-022-08012-7 http://doi.org/10.1038/s41598-022-08012-7

JI J T , WU H , FENG X B , et al . Dynamics of acquired resistance to nivolumab therapies varies from administration strategies [J ] . Clin Ther , 2021 , 43 ( 12 ): 2088 - 2103 . DOI: 10.1016/j.clinthera.2021.10.004 http://doi.org/10.1016/j.clinthera.2021.10.004

WEST J B , DINH M N , BROWN J S , et al . Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy [J ] . Clin Cancer Res , 2019 , 25 ( 14 ): 4413 - 4421 . DOI: 10.1158/1078-0432.CCR-19-0006 http://doi.org/10.1158/1078-0432.CCR-19-0006

MA Y , NEWTON P K . Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules [J ] . Phys Rev E , 2021 , 103 (): 032408 . DOI: 10.1103/PhysRevE.103.032408 http://doi.org/10.1103/PhysRevE.103.032408 https://link.aps.org/doi/10.1103/PhysRevE.103.032408 https://link.aps.org/doi/10.1103/PhysRevE.103.032408

KIM E , BROWN J S , EROGLU Z , et al . Adaptive therapy for metastatic melanoma: predictions from patient calibrated mathematical models [J ] . Cancers (Basel) , 2021 , 13 ( 4 ): 823 . DOI: 10.3390/cancers13040823 http://doi.org/10.3390/cancers13040823 https://www.mdpi.com/2072-6694/13/4/823 https://www.mdpi.com/2072-6694/13/4/823

WANG Z H , BUTNER J D , KERKETTA R , et al . Simulating cancer growth with multiscale agent-based modeling [J ] . Semin Cancer Biol , 2015 , 30 : 70 - 78 . DOI: 10.1016/j.semcancer.2014.04.001 http://doi.org/10.1016/j.semcancer.2014.04.001

DEISBOECK T S , WANG Z , MACKLIN P , et al . Multiscale cancer modeling [J ] . Annu Rev Biomed Eng , 2011 , 13 : 127 - 155 . DOI: 10.1146/annurev-bioeng-071910-124729 http://doi.org/10.1146/annurev-bioeng-071910-124729

JOHNSON D , MCKEEVER S , STAMATAKOS G , et al . Dealing with diversity in computational cancer modeling [J ] . Cancer Inform , 2013 , 12 : 115 - 124 .

REJNIAK K A , ANDERSON A R A . Hybrid models of tumor growth [J ] . Wiley Interdiscip Rev Syst Biol Med , 2011 , 3 ( 1 ): 115 - 125 . DOI: 10.1002/wsbm.v3.1 http://doi.org/10.1002/wsbm.v3.1 https://onlinelibrary.wiley.com/toc/1939005x/3/1 https://onlinelibrary.wiley.com/toc/1939005x/3/1

CHISHOLM R H , LORENZI T , CLAIRAMBAULT J . Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation [J ] . Biochim Biophys Acta , 2016 , 1860 ( 11 Pt B ): 2627 - 2645 . DOI: 10.1016/j.bbagen.2016.06.009 http://doi.org/10.1016/j.bbagen.2016.06.009

YOU L , BROWN J S , THUIJSMAN F , et al . Spatial vs non-spatial eco-evolutionary dynamics in a tumor growth model [J ] . J Theor Biol , 2017 , 435 : 78 - 97 . DOI: 10.1016/j.jtbi.2017.08.022 http://doi.org/10.1016/j.jtbi.2017.08.022 https://linkinghub.elsevier.com/retrieve/pii/S0022519317303971 https://linkinghub.elsevier.com/retrieve/pii/S0022519317303971

STROBL M A R , GALLAHER J , WEST J , et al . Spatial structure impacts adaptive therapy by shaping intra-tumoral competition [J ] . Commun Med (Lond) , 2022 , 2 : 46 .

FU X , ZHAO Y , LOPEZ J I , et al . Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx renal study [J ] . Nat Ecol Evol , 2022 , 6 ( 1 ): 88 - 102 . DOI: 10.1038/s41559-021-01586-x http://doi.org/10.1038/s41559-021-01586-x

GALLAHER J A , ENRIQUEZ-NAVAS P M , LUDDY K A , et al . Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies [J ] . Cancer Res , 2018 , 78 ( 8 ): 2127 - 2139 . DOI: 10.1158/0008-5472.CAN-17-2649 http://doi.org/10.1158/0008-5472.CAN-17-2649

STOREY K M , JACKSON T L . An agent-based model of combination oncolytic viral therapy and anti-PD-1 immunotherapy reveals the importance of spatial location when treating glioblastoma [J ] . Cancers (Basel) , 2021 , 13 ( 21 ): 5314 . DOI: 10.3390/cancers13215314 http://doi.org/10.3390/cancers13215314 https://www.mdpi.com/2072-6694/13/21/5314 https://www.mdpi.com/2072-6694/13/21/5314

PIN C , COLLINS T , GIBBS M , et al . Systems modeling to quantify safety risks in early drug development: using bifurcation analysis and agent-based modeling as examples [J ] . AAPS J , 2021 , 23 ( 4 ): 77 . DOI: 10.1208/s12248-021-00580-2 http://doi.org/10.1208/s12248-021-00580-2

ROJAS-DOMÍNGUEZ A , ARROYO-DUARTE R , RINCÓN-VIEYRA F , et al . Modeling cancer immunoediting in tumor microenvironment with system characterization through the Ising-model Hamiltonian [J ] . BMC Bioinformatics , 2022 , 23 ( 1 ): 200 . DOI: 10.1186/s12859-022-04731-w http://doi.org/10.1186/s12859-022-04731-w

GATENBY R A , BROWN J S . The evolution and ecology of resistance in cancer therapy [J ] . Cold Spring Harb Perspect Med , 2020 , 10 ( 11 ): a040972 . DOI: 10.1101/cshperspect.a040972 http://doi.org/10.1101/cshperspect.a040972 http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/cshperspect.a040972 http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/cshperspect.a040972

MALEY C C , REID B J , FORREST S . Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity [J ] . Cancer Epidemiol Biomarkers Prev , 2004 , 13 ( 8 ): 1375 - 1384 . DOI: 10.1158/1055-9965.1375.13.8 http://doi.org/10.1158/1055-9965.1375.13.8 https://aacrjournals.org/cebp/article/13/8/1375/116106/Cancer-Prevention-Strategies-That-Address-the https://aacrjournals.org/cebp/article/13/8/1375/116106/Cancer-Prevention-Strategies-That-Address-the

SCHWEIZER M T , ANTONARAKIS E S , WANG H , et al . Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study [J ] . Sci Transl Med , 2015 , 7 ( 269 ): 269ra2 .

SENA L A , WANG H , LIM SCM S J , et al . Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy [J ] . Eur J Cancer , 2021 , 144 : 302 - 309 . DOI: 10.1016/j.ejca.2020.11.043 http://doi.org/10.1016/j.ejca.2020.11.043

GATENBY R A , BROWN J , VINCENT T . Lessons from applied ecology: cancer control using an evolutionary double bind [J ] . Cancer Res , 2009 , 69 ( 19 ): 7499 - 7502 . DOI: 10.1158/0008-5472.CAN-09-1354 http://doi.org/10.1158/0008-5472.CAN-09-1354

ANTONIA S J , MIRZA N , FRICKE I , et al . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J ] . Clin Cancer Res , 2006 , 12 ( 3 ): 878 - 887 . DOI: 10.1158/1078-0432.CCR-05-2013 http://doi.org/10.1158/1078-0432.CCR-05-2013 https://aacrjournals.org/clincancerres/article/12/3/878/194198/Combination-of-p53-Cancer-Vaccine-with https://aacrjournals.org/clincancerres/article/12/3/878/194198/Combination-of-p53-Cancer-Vaccine-with

STANKOVÁ K , BROWN J S , DALTON W S , et al . Optimizing cancer treatment using game theory: a review [J ] . JAMA Oncol , 2019 , 5 ( 1 ): 96 - 103 . DOI: 10.1001/jamaoncol.2018.3395 http://doi.org/10.1001/jamaoncol.2018.3395

Views

1351

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

乳腺癌精准治疗的现状与展望

Related Author

Precision treatment in breast cancer: current advancements

future directions WU Wei

ABUDUREHEIYIMU Nilupai

FAN Ying

Related Institution

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰